Please login to the form below

Not currently logged in
Email:
Password:

adalimumab

This page shows the latest adalimumab news and features for those working in and with pharma, biotech and healthcare.

AbbVie builds case for arthritis blockbuster-in-waiting upadacitinib

AbbVie builds case for arthritis blockbuster-in-waiting upadacitinib

The orally-administered JAK1 inhibitor has already been shown in phase III trials to be more effective than AbbVie’s injectable TNF blocker Humira (adalimumab) when it comes to clinical responses

Latest news

More from news
Approximately 22 fully matching, plus 174 partially matching documents found.

Latest Intelligence

  • The sound of silence puts the squeeze on generics and biosimilars The sound of silence puts the squeeze on generics and biosimilars

    drugs - from Adalimumab to Rituximab - go off-patent and boost savings across eight European nations to 33.4bn over the next three years.

  • Can biosimilars live up to the hype? Can biosimilars live up to the hype?

    We have some big drugs, such as adalimumab [AbbVie's Humira], going off patent so that pressure will intensify,” he adds. “

  • Cost containment and the German market Cost containment and the German market

    The main sales drivers are biopharmaceutical medicines like the monoclonal antibody adalimumab, TNF-alpha inhibitor etanercept as well as the oncologic drugs imatinib and enzalutamide. ... This year the patent for the top seller adalimumab is going to

  • Biosimilars - the same, but different? Biosimilars - the same, but different?

    drugs Humira (adalimumab) and Enbrel (etanercept) - last year's first and third best selling drugs respectively - are also in the biosimilar firing line.

  • AbbVie: New firm, new thinking AbbVie: New firm, new thinking

    The result was AbbVie, which launched on the stock exchange in January 2013 with 12, 000 employees and an estimated $18bn in annual revenues – headed by arthritis blockbuster Humira (adalimumab), the

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Infographic: RA Perceptions

    adalimumab) to continue to lead the market and be used to treat over a third of Rheumatoid Arthritis (RA) patients in three years’ time.

  • The Biosimilar Challenge

    These include the infliximab biosimilars Inflectra and Remsima, the etanercept biosimilar Benepali (launched last year) and biosimilars to adalimumab, filgrastim and bevacizumab preparing to launch on the horizon.

  • Biosimilars: Getting the flock to market

    The greatest attraction, naturally, is high-revenue anti-TNF agents like MabThera (rituximab) and Humira (adalimumab), for many years the world's most valuable drug.

  • The Biosimilar Challenge

    These include the infliximab biosimilars Inflectra and Remsima, the etanercept biosimilar Benepali (launched last year) and biosimilars to adalimumab, filgrastim and bevacizumab preparing to launch on the horizon.

  • Infographic: RA Perceptions

    adalimumab) to continue to lead the market and be used to treat over a third of Rheumatoid Arthritis (RA) patients in three years’ time.

More from PMHub
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics